Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.
Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), according to researchers at The University of Texas MD Anderson Cancer Center.
Patients with stage 1–3 non-small cell lung cancer (NSCLC) given a combination immunotherapy prior to surgery (neoadjuvant) had a better major pathological response (10% or less residual cancer) when the cancer was removed than those who took a single immunotherapy agent alone, according to results of a novel multicenter phase 2 NeoCOAST platform trial that included two investigators from the Johns Hopkins Kimmel Cancer Center and its Bloomberg-Kimmel Institute for Cancer Immunotherapy.
University of Liverpool researchers have secured £2.66m Medical Research Council funding to clinically test a novel immunotherapeutic strategy for non-small cell lung cancer – one of the most deadly cancers.
A study presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer revealed that key reproductive factors such as early menopause, shortened reproductive span, and early age at first birth are associated with elevated risks of lung cancer in women.
The International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2023 in Singapore is set to witness a monumental breakthrough in the field of metastatic non-small cell lung cancer (NSCLC) treatment.
The immunotherapy drug, durvalumab, has been the standard of care for patients with stage III non-small cell lung cancer(NSCLC) to improve survival, when prescribed after chemotherapy and radiation therapy.
Amgen today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) will review data supporting the supplemental New Drug Application (sNDA) for the full approval of LUMAKRAS® (sotorasib) for adults with previously treated locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC) at a meeting on Oct. 5, 2023.
Fresh discoveries about a type of immune cells could give lung cancer patients a more accurate prognosis and better identify who will benefit from immunotherapies.
A new editorial paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, "Are cis-spliced fusion proteins pathological in more aggressive luminal breast cancer?"
While pembrolizumab is an approved treatment for patients with stage III non-small cell lung cancer (NSCLC), only some patients respond to this therapy. Treatment failure, researchers say, is often caused by differences in the tumor microenvironment.
A global study, led by UCL and UCLH and sponsored by Roche, has shown that the cancer immunotherapy atezolizumab significantly improved the overall survival of advanced stage non-small cell lung cancer patients who were not able to be treated with platinum-containing chemotherapy, when compared to single-agent chemotherapy.
Researchers of the University of Barcelona and the Institute of Bioengineering of Catalonia have identified new biomarkers for non-small cell lung cancer, the most common lung cancer.
A new research paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, "Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)."
A clinical trial led by Yale Cancer Center shows that the drug osimertinib, a targeted therapy for non-small cell lung cancer, improved rates of survival and reduced risk of recurrence in patients after surgery.
At the 2023 American Society for Clinical Oncology Annual Meeting—to be held June 2-6 in Chicago, Illinois—Fred Hutchinson Cancer Center experts will present research spanning survivorship, advances in treatments and clinical trials, how access to cancer care affects outcomes, integrative medicine and more.
Over the past decade, the approval of immune checkpoint inhibitors has revolutionized treatment for patients with advanced lung cancer, helping many live longer lives and improving overall survival for the disease.
he National Comprehensive Cancer Network-;a not-for-profit alliance of leading cancer centers in the United States-;today announced the signing of a Memo of Understanding (MOU) with Vietnam National Cancer Hospital ("K Hospital") and the Vietnam Cancer Association to work together to improve standards for cancer care throughout the country.
Chemotherapy-induced peripheral neuropathy (CIPN) – nerve pain, tingling, or numbness in the hands or feet – is a common side effect of certain cancer treatments, including two drugs frequently used to treat cancer – the taxanes paclitaxel and docetaxel.
Healthy cells can only divide a limited number of times during an organism's lifetime. In contrast, tumor cells are immortal: they proliferate indefinitely and uncontrollably, and this is the defining characteristic of cancer.
Novel anti-cancer therapies were not accessible to more than half of the patients in England who were diagnosed with non-small cell lung cancer, according to a new study published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer.